Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

By J. Vos, J. Elbers, O. Krijgsman, J. Traets, X. Qiao, A. M. van der Leun, Yoni Lubeck, I. M. Seignette, L. Smit, S. Willems and 24 more. 2021

Subfields: Immunology, Oncology, Otorhinolaryngology

Citations in the corpus

• Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “…treated with two doses of immune checkpoint blockade (ICB) using Nivolumab or Nivolumab plus a single dose of Ipilimumab prior to surgery, demonstrated a highly discordant response between the primary tumor and lymph node metastases as measured by PET-CT activity following immunotherapy [13].”